Thursday November 13, 2025

• 11:00 AM – 11:45 AM

  Precision Medicine in NMSC - Biomarkers, Molecular Profiling, and Personalized Therapy

  • Faculty
    • 
      Justin Moyers MD

  Learning Objectives:

  • Identify which patients with advanced cSCC or BCC should receive molecular testing and which assays are most useful (eg, IHC, MSI/TMB, and NGS) 

  • Recognize key actionable biomarkers in NMSC and the therapies they inform (e.g., PTCH1/SMO → hedgehog inhibitors; high TMB/MMR‑d/PD‑L1 → PD‑1 therapy; rare NTRK fusions → TRK inhibitors) 

  • Interpret a basic molecular report and determine whether findings should change first‑ or second‑line treatment selection or prompt a clinical‑trial referral 

  • Outline a simple testing‑to‑treatment workflow (specimen choice, turnaround time, documentation/coverage, and multidisciplinary handoffs) for community practice 

  • Communicate the benefits and limitations of precision approaches in plain language so patients can participate in shared decision‑making 

  Non-Accredited Educational Session With Q&A
• 12:00 PM – 12:45 PM

  Multidisciplinary Coordination - Dermatology, Oncology, and Surgery in Advanced NMSC

  • Faculty
    • 
      Harrison Nguyen MD, MBA, MPH

  Learning Objectives:

  • Define the core roles of dermatology, medical oncology, and surgery in managing advanced NMSC (aCSCC/aBCC) 

  • Identify three clinical triggers that should prompt same‑week multidisciplinary coordination 

  • Outline a basic care pathway for aCSCC vs aBCC and who typically leads at each step. 

  • Apply a concise handoff checklist to standardize referrals and information exchange across the team 

  Non-Accredited Educational Session With Q&A
• 1:00 PM – 2:00 PM

  Reserved Sponsor Presentation: Innovation Theater

  Sponsored by:

  
• 2:15 PM – 3:00 PM

  Optimizing Local and Systemic Approaches: Where Surgery, Radiation, and IO Intersect

  • Faculty
    • 
      Vishal Patel MD

  Learning Objectives:

  • Differentiate treatment pathways for advanced NMSC where surgery, radiation, or systemic therapy are used alone vs in combination (eg, neoadjuvant IO before surgery, adjuvant RT after resection) 

  • Identify clinical scenarios where multidisciplinary input is needed to select or sequence local and systemic approaches (eg, large tumors, positive margins, nodal disease, inoperability) 

  • Interpret key clinical considerations that influence treatment selection—such as tumor location, depth, patient comorbidities, and goals of care 

  • Outline practical workflows for integrating IO with surgery or radiation, including timing of referrals, documentation of intent (eg, neoadjuvant vs palliative), and pre/post-treatment monitoring 

  • Use case-based discussions to illustrate decision-making in challenging scenarios, such as borderline resectable disease, prior radiation exposure, or recurrence after surgery 

  Non-Accredited Educational Session With Q&A
• 3:15 PM – 4:00 PM

  Managing Special Populations - Geriatric, Immunosuppressed, and Transplant Patients With aNMSC

  • Faculty
    • 
      Noah Hornick MD, PhD

  Learning Objectives:

  • Recognize key risk–benefit considerations for IO in older or frail adults (comorbidities, polypharmacy, goals of care) 

  • Describe practical strategies to use or modify immunotherapy in immunosuppressed patients, including when to adjust baseline immunosuppression 

  • Identify early warning signs and tailored management approaches for immune‑related AEs in these high‑risk groups 

  • Coordinate multidisciplinary care with transplant teams and relevant subspecialists to balance oncologic control and graft/organ safety 

  • Apply shared decision‑making tools that incorporate patient preferences, caregiver input, and quality‑of‑life priorities 

  Non-Accredited Educational Session With Q&A